Comparative transcriptome of normal and cancer-associated fibroblasts.
Humans
Cancer-Associated Fibroblasts
/ metabolism
Male
Transcriptome
Prostatic Neoplasms
/ genetics
Gene Expression Profiling
Fibroblasts
/ metabolism
Tumor Microenvironment
/ genetics
MicroRNAs
/ genetics
RNA, Long Noncoding
/ genetics
Biomarkers, Tumor
/ genetics
Gene Expression Regulation, Neoplastic
RNA, Messenger
/ genetics
Prostatic Hyperplasia
/ genetics
Cancer-associated fibroblasts
Chemoresistance
LINCRNA
Non-coding RNA
Prostate cancer
Tumor microenvironment
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
05 Oct 2024
05 Oct 2024
Historique:
received:
12
06
2024
accepted:
27
09
2024
medline:
6
10
2024
pubmed:
6
10
2024
entrez:
5
10
2024
Statut:
epublish
Résumé
The characteristics of a tumor are largely determined by its interaction with the surrounding micro-environment (TME). TME consists of both cellular and non-cellular components. Cancer-associated fibroblasts (CAFs) are a major component of the TME. They are a source of many secreted factors that influence the survival and progression of tumors as well as their response to drugs. Identification of markers either overexpressed in CAFs or unique to CAFs would pave the way for novel therapeutic strategies that in combination with conventional chemotherapy are likely to have better patient outcome. Fibroblasts have been derived from Benign Prostatic Hyperplasia (BPH) and prostate cancer. RNA from these has been used to perform a transcriptome analysis in order to get a comparative profile of normal and cancer-associated fibroblasts. The study has identified 818 differentially expressed mRNAs and 17 lincRNAs between normal and cancer-associated fibroblasts. Also, 15 potential lincRNA-miRNA-mRNA combinations have been identified which may be potential biomarkers. This study identified differentially expressed markers between normal and cancer-associated fibroblasts that would help in targeted therapy against CAFs/derived factors, in combination with conventional therapy. However, this would in future need more experimental validation.
Sections du résumé
BACKGROUND
BACKGROUND
The characteristics of a tumor are largely determined by its interaction with the surrounding micro-environment (TME). TME consists of both cellular and non-cellular components. Cancer-associated fibroblasts (CAFs) are a major component of the TME. They are a source of many secreted factors that influence the survival and progression of tumors as well as their response to drugs. Identification of markers either overexpressed in CAFs or unique to CAFs would pave the way for novel therapeutic strategies that in combination with conventional chemotherapy are likely to have better patient outcome.
METHODS
METHODS
Fibroblasts have been derived from Benign Prostatic Hyperplasia (BPH) and prostate cancer. RNA from these has been used to perform a transcriptome analysis in order to get a comparative profile of normal and cancer-associated fibroblasts.
RESULTS
RESULTS
The study has identified 818 differentially expressed mRNAs and 17 lincRNAs between normal and cancer-associated fibroblasts. Also, 15 potential lincRNA-miRNA-mRNA combinations have been identified which may be potential biomarkers.
CONCLUSIONS
CONCLUSIONS
This study identified differentially expressed markers between normal and cancer-associated fibroblasts that would help in targeted therapy against CAFs/derived factors, in combination with conventional therapy. However, this would in future need more experimental validation.
Identifiants
pubmed: 39369238
doi: 10.1186/s12885-024-13006-x
pii: 10.1186/s12885-024-13006-x
doi:
Substances chimiques
MicroRNAs
0
RNA, Long Noncoding
0
Biomarkers, Tumor
0
RNA, Messenger
0
Types de publication
Journal Article
Comparative Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1231Subventions
Organisme : Indian Council for Medical Research Government of India
ID : 2019-0937
Informations de copyright
© 2024. The Author(s).
Références
de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41(3):374–403.
doi: 10.1016/j.ccell.2023.02.016
pubmed: 36917948
Patel H, et al. Modulating secreted components of tumor microenvironment: a masterstroke in tumor therapeutics. Cancer Biol Ther. 2018;19(1):3–12.
doi: 10.1080/15384047.2017.1394538
pubmed: 29219656
Baghban R, et al. Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun Signal. 2020;18(1):59.
doi: 10.1186/s12964-020-0530-4
pubmed: 32264958
pmcid: 7140346
Anderson NM, Simon MC. The tumor microenvironment. Curr Biol. 2020;30(16):R921-5.
doi: 10.1016/j.cub.2020.06.081
pubmed: 32810447
pmcid: 8194051
Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther. 2021;221: 107753.
doi: 10.1016/j.pharmthera.2020.107753
pubmed: 33259885
Brennen WN, Isaacs JT, Denmeade SR. Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Mol Cancer Ther. 2012;11(2):257–66.
doi: 10.1158/1535-7163.MCT-11-0340
pubmed: 22323494
pmcid: 3586189
Mao X, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021;20(1):131.
doi: 10.1186/s12943-021-01428-1
pubmed: 34635121
pmcid: 8504100
Bu L, et al. Functional diversity of cancer-associated fibroblasts in modulating drug resistance. Cancer Sci. 2020;111(10):3468–77.
doi: 10.1111/cas.14578
pubmed: 33044028
pmcid: 7541012
Sun Y, et al. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med. 2012;18(9):1359–68.
doi: 10.1038/nm.2890
pubmed: 22863786
pmcid: 3677971
Sun Y, et al. SFRP2 augments WNT16B signaling to promote therapeutic resistance in the damaged tumor microenvironment. Oncogene. 2016;35(33):4321–34.
doi: 10.1038/onc.2015.494
pubmed: 26751775
pmcid: 4994019
Zhang D, et al. Tumor-stroma IL1β-IRAK4 feedforward circuitry drives tumor fibrosis, chemoresistance, and poor prognosis in pancreatic cancer. Cancer Res. 2018;78(7):1700–12.
doi: 10.1158/0008-5472.CAN-17-1366
pubmed: 29363544
pmcid: 5890818
Qiao Y, et al. IL6 derived from cancer-associated fibroblasts promotes chemoresistance via CXCR7 in esophageal squamous cell carcinoma. Oncogene. 2018;37(7):873–83.
doi: 10.1038/onc.2017.387
pubmed: 29059160
Lotti F, et al. Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A. J Exp Med. 2013;210(13):2851–72.
doi: 10.1084/jem.20131195
pubmed: 24323355
pmcid: 3865474
Calon A, et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat Genet. 2015;47(4):320–9.
doi: 10.1038/ng.3225
pubmed: 25706628
Olive KP, et al. Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;324(5933):1457–61.
doi: 10.1126/science.1171362
pubmed: 19460966
pmcid: 2998180
Tang YA, et al. Hypoxic tumor microenvironment activates GLI2 via HIF-1α and TGF-β2 to promote chemoresistance in colorectal cancer. Proc Natl Acad Sci U S A. 2018;115(26):E5990-9.
doi: 10.1073/pnas.1801348115
pubmed: 29891662
pmcid: 6042102
Sansone P, et al. Evolution of Cancer stem-like cells in endocrine-resistant metastatic breast cancers is mediated by Stromal Microvesicles. Cancer Res. 2017;77(8):1927–41.
doi: 10.1158/0008-5472.CAN-16-2129
pubmed: 28202520
pmcid: 5392366
Yu T, et al. Cytoplasmic GPER translocation in cancer-associated fibroblasts mediates cAMP/PKA/CREB/glycolytic axis to confer tumor cells with multidrug resistance. Oncogene. 2017;36(15):2131–45.
doi: 10.1038/onc.2016.370
pubmed: 27721408
Asif PJ et al. The Role of Cancer-Associated Fibroblasts in Cancer Invasion and Metastasis. Cancers (Basel), 2021;13(18).
Jena BC, et al. Cancer associated fibroblast mediated chemoresistance: a paradigm shift in understanding the mechanism of tumor progression. Biochim Biophys Acta Rev Cancer. 2020;1874(2): 188416.
doi: 10.1016/j.bbcan.2020.188416
pubmed: 32822826
Rizzolio S, Giordano S, Corso S. The importance of being CAFs (in cancer resistance to targeted therapies). J Exp Clin Cancer Res. 2022;41(1):319.
doi: 10.1186/s13046-022-02524-w
pubmed: 36324182
pmcid: 9632140
Zheng Y, et al. NPInter v5.0: ncRNA interaction database in a new era. Nucleic Acids Res. 2023;51(D1):D232-9.
doi: 10.1093/nar/gkac1002
pubmed: 36373614
NPInter. Available from: http://bigdata.ibp.ac.cn/npinter5/ .
miRDB. Available from: https://mirdb.org/ .
Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009;9(4):239–52.
doi: 10.1038/nrc2618
pubmed: 19279573
Cheteh EH, et al. Human cancer-associated fibroblasts enhance glutathione levels and antagonize drug-induced prostate cancer cell death. Cell Death Dis. 2017;8(6):e2848.
doi: 10.1038/cddis.2017.225
pubmed: 28569790
pmcid: 5520886
Linxweiler J, et al. Cancer-associated fibroblasts stimulate primary tumor growth and metastatic spread in an orthotopic prostate cancer xenograft model. Sci Rep. 2020;10(1):12575.
doi: 10.1038/s41598-020-69424-x
pubmed: 32724081
pmcid: 7387494
Roma-Rodrigues C, et al. Targeting tumor microenvironment for cancer therapy. Int J Mol Sci. 2019;20(4):840.
doi: 10.3390/ijms20040840
pubmed: 30781344
pmcid: 6413095
Busby J, et al. Angiotensin receptor blocker use and gastro-oesophageal cancer survival: a population-based cohort study. Aliment Pharmacol Ther. 2018;47(2):279–88.
doi: 10.1111/apt.14388
pubmed: 29105106
Coulson R, et al. The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma. Oncotarget. 2017;8(12):18640–56.
doi: 10.18632/oncotarget.15553
pubmed: 28416734
pmcid: 5386636
Diop-Frimpong B, et al. Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc Natl Acad Sci U S A. 2011;108(7):2909–14.
doi: 10.1073/pnas.1018892108
pubmed: 21282607
pmcid: 3041115
Cassinelli G, et al. Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models. Biochem Pharmacol. 2013;85(10):1424–32.
doi: 10.1016/j.bcp.2013.02.023
pubmed: 23466421
Ritchie JP, et al. SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Clin Cancer Res. 2011;17(6):1382–93.
doi: 10.1158/1078-0432.CCR-10-2476
pubmed: 21257720
pmcid: 3060291
Chu QS, et al. A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas. Invest New Drugs. 2007;25(4):359–67.
doi: 10.1007/s10637-006-9031-6
pubmed: 17237909
Gu Y, et al. Inhibition of breast cancer cell extracellular matrix degradative activity by chemically modified tetracyclines. Ann Med. 2005;37(6):450–60.
doi: 10.1080/07853890500300386
pubmed: 16203617
Fingleton B. CMT-3. CollaGenex. Curr Opin Investig Drugs. 2003;4(12):1460–7.
pubmed: 14763133
Scannevin RH, et al. Discovery of a highly selective chemical inhibitor of matrix metalloproteinase-9 (MMP-9) that allosterically inhibits zymogen activation. J Biol Chem. 2017;292(43):17963–74.
doi: 10.1074/jbc.M117.806075
pubmed: 28860188
pmcid: 5663893
Ling B, et al. A novel immunotherapy targeting MMP-14 limits hypoxia, immune suppression and metastasis in triple-negative breast cancer models. Oncotarget. 2017;8(35):58372–85.
doi: 10.18632/oncotarget.17702
pubmed: 28938563
pmcid: 5601659
Szebeni GJ et al. Pro-tumoral inflammatory myeloid cells as emerging therapeutic targets. Int J Mol Sci, 2016. 17(11).
Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41(1):49–61.
doi: 10.1016/j.immuni.2014.06.010
pubmed: 25035953
pmcid: 4137410
Komohara Y, et al. Tumor-associated macrophages: potential therapeutic targets for anti-cancer therapy. Adv Drug Deliv Rev. 2016;99Pt B:p180-185.
doi: 10.1016/j.addr.2015.11.009
Holen I, et al. IL-1 drives breast cancer growth and bone metastasis in vivo. Oncotarget. 2016;7(46):75571–84.
doi: 10.18632/oncotarget.12289
pubmed: 27765923
pmcid: 5342762
Tulotta C, Ottewell P. The role of IL-1B in breast cancer bone metastasis. Endocr Relat Cancer. 2018;25(7):R421-434.
doi: 10.1530/ERC-17-0309
pubmed: 29760166
pmcid: 5987176
Yan WL, et al. Activation of GM-CSF and TLR2 signaling synergistically enhances antigen-specific antitumor immunity and modulates the tumor microenvironment. J Immunother Cancer. 2021;9(10):e002758.
doi: 10.1136/jitc-2021-002758
pubmed: 34599024
pmcid: 8488721
Shiravand Y, et al. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022;29(5):3044–60.
doi: 10.3390/curroncol29050247
pubmed: 35621637
pmcid: 9139602
Boohaker RJ, et al. Rational design and development of a peptide inhibitor for the PD-1/PD-L1 interaction. Cancer Lett. 2018;434:11–21.
doi: 10.1016/j.canlet.2018.04.031
pubmed: 29920293
Ishii N, et al. Conophylline suppresses pancreatic cancer desmoplasia and cancer-promoting cytokines produced by cancer-associated fibroblasts. Cancer Sci. 2019;110(1):334–44.
doi: 10.1111/cas.13847
pubmed: 30353606
Sounni NE, Noel A. Targeting the tumor microenvironment for cancer therapy. Clin Chem. 2013;59(1):85–93.
doi: 10.1373/clinchem.2012.185363
pubmed: 23193058
Xing F, Saidou J, Watabe K. Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci (Landmark Ed). 2010;15(1):166–79.
doi: 10.2741/3613
pubmed: 20036813
De Wever O, et al. Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer. 2008;123(10):2229–38.
doi: 10.1002/ijc.23925
pubmed: 18777559
Muchlińska A, et al. Alpha-smooth muscle actin-positive cancer-associated fibroblasts secreting osteopontin promote growth of luminal breast cancer. Cell Mol Biol Lett. 2022;27(1):45.
doi: 10.1186/s11658-022-00351-7
pubmed: 35690734
pmcid: 9188043
Gilardi L, et al. Imaging Cancer-Associated fibroblasts (CAFs) with FAPi PET. Biomedicines. 2022;10(3):523.
doi: 10.3390/biomedicines10030523
pubmed: 35327325
pmcid: 8945705
Ti W, Wang J, Cheng Y. The interaction between ong non-coding RNAs and Cancer-Associated fibroblasts in lung cancer. Front Cell Dev Biol. 2021;9:714125.
doi: 10.3389/fcell.2021.714125
pubmed: 35087824
Ransohoff JD, Wei Y, Khavari PA. The functions and unique features of long intergenic non-coding RNA. Nat Rev Mol Cell Biol. 2018;19(3):143–57.
doi: 10.1038/nrm.2017.104
pubmed: 29138516
Sebastian-delaCruz M, et al. The role of lncRNAs in gene expression regulation through mRNA stabilization. Non-Coding RNA. 2021;7(1):3.
doi: 10.3390/ncrna7010003
pubmed: 33466464
pmcid: 7839045
Qian Y, Shi L, Luo Z. Long non-coding RNAs in Cancer: implications for diagnosis, prognosis, and Therapy. Front Med (Lausanne). 2020;7:612393.
doi: 10.3389/fmed.2020.612393
pubmed: 33330574
Gao N, et al. Long non-coding RNAs: the Regulatory mechanisms, research strategies, and future directions in cancers. Front Oncol. 2020;10: 598817.
doi: 10.3389/fonc.2020.598817
pubmed: 33392092
pmcid: 7775490
Beylerli O, et al. Long noncoding RNAs as promising biomarkers in cancer. Noncoding RNA Res. 2022;7(2):66–70.
doi: 10.1016/j.ncrna.2022.02.004
pubmed: 35310927
pmcid: 8891810
Akers JC, et al. Biogenesis of extracellular vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies. J Neurooncol. 2013;113(1):1–11.
doi: 10.1007/s11060-013-1084-8
pubmed: 23456661
pmcid: 5533094
Su YJ, et al. Circulating long noncoding RNA as a potential target for prostate ancer. Int J Mol Sci. 2015;16(6):13322–38.
doi: 10.3390/ijms160613322
pubmed: 26110379
pmcid: 4490497
Bolha L, Ravnik-Glavač M, Glavač D. Long noncoding RNAs as biomarkers in ancer. Dis Markers. 2017;2017:p7243968.
doi: 10.1155/2017/7243968
Necsulea A, et al. The evolution of lncRNA repertoires and expression patterns in tetrapods. Nature. 2014;505(7485):635–40.
doi: 10.1038/nature12943
pubmed: 24463510
Lee JT. Epigenetic regulation by long noncoding RNAs. Science. 2012;338(6113):1435–9.
doi: 10.1126/science.1231776
pubmed: 23239728
Ke X, et al. Construction and analysis of the lncRNA-miRNA-mRNA network based on competing endogenous RNA in Atrial Fibrillation. Front Cardiovasc Med. 2022;9: 791156.
doi: 10.3389/fcvm.2022.791156
pubmed: 35141302
pmcid: 8818759
Luo J, et al. LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2/STAT3 signaling. Nat Commun. 2019;10(1):2571.
doi: 10.1038/s41467-019-09784-9
pubmed: 31189930
pmcid: 6561926
Salameh A, et al. PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3. Proc Natl Acad Sci U S A. 2015;112(27):8403–8.
doi: 10.1073/pnas.1507882112
pubmed: 26080435
pmcid: 4500257
Ren S, et al. Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer. Eur J Cancer. 2013;49(13):2949–59.
doi: 10.1016/j.ejca.2013.04.026
pubmed: 23726266
Pal G, et al. Long noncoding RNA from PVT1 exon 9 is overexpressed in prostate Cancer and induces Malignant Transformation and Castration Resistance in prostate epithelial cells. Genes. 2019;10(12): 964.
doi: 10.3390/genes10120964
pubmed: 31766781
pmcid: 6969942
Zhang Y, et al. An androgen reduced transcript of LncRNA GAS5 promoted prostate cancer proliferation. PLoS ONE. 2017;12(8): e0182305.
doi: 10.1371/journal.pone.0182305
pubmed: 28771526
pmcid: 5542543
Kidd SG, et al. High expression of SCHLAP1 in primary prostate cancer is an independent predictor of biochemical recurrence, despite substantial heterogeneity. Neoplasia. 2021;23(6):634–41.
doi: 10.1016/j.neo.2021.05.012
pubmed: 34107378
pmcid: 8192444
Zheng R, et al. Exosome-transmitted long non-coding RNA PTENP1 suppresses bladder cancer progression. Mol Cancer. 2018;17(1):143.
doi: 10.1186/s12943-018-0880-3
pubmed: 30285771
pmcid: 6169076
Xue M, et al. Long non-coding RNA urothelial cancer-associated 1 promotes bladder cancer cell migration and invasion by way of the hsa-miR-145-ZEB1/2-FSCN1 pathway. Cancer Sci. 2016;107(1):18–27.
doi: 10.1111/cas.12844
pubmed: 26544536
Liu D, et al. LncRNA SPRY4-IT1 sponges mir-101-3p to promote proliferation and metastasis of bladder cancer cells through up-regulating EZH2. Cancer Lett. 2017;388:281–91.
doi: 10.1016/j.canlet.2016.12.005
pubmed: 27998761
Sun X, et al. Long non-coding RNA HOTAIR regulates cyclin J via inhibition of microRNA-205 expression in bladder cancer. Cell Death Dis. 2015;6(10):e1907.
doi: 10.1038/cddis.2015.269
pubmed: 26469956
pmcid: 4632298
Zhang K, et al. Circulating lncRNA H19 in plasma as a novel biomarker for breast cancer. Cancer Biomark. 2016;17(2):187–94.
doi: 10.3233/CBM-160630
pubmed: 27540977
Younger ST, Rinn JL. Lnc’-ing enhancers to MYC regulation. Cell Res. 2014;24(6):643–4.
doi: 10.1038/cr.2014.54
pubmed: 24777251
pmcid: 4042177
Ling H, et al. CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res. 2013;23(9):1446–61.
doi: 10.1101/gr.152942.112
pubmed: 23796952
pmcid: 3759721
Xu C, et al. MALAT-1: a long non-coding RNA and its important 3’ end functional motif in colorectal cancer metastasis. Int J Oncol. 2011;39(1):169–75.
pubmed: 21503572
Zhang X, et al. A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells. J Clin Endocrinol Metab. 2003;88(11):5119–26.
doi: 10.1210/jc.2003-030222
pubmed: 14602737
Kogo R, et al. Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer Res. 2011;71(20):6320–6.
doi: 10.1158/0008-5472.CAN-11-1021
pubmed: 21862635
Zhang J, et al. HOTAIR contributes to the carcinogenesis of gastric cancer via modulating cellular and exosomal miRNAs level. Cell Death Dis. 2020;11(9):780.
doi: 10.1038/s41419-020-02946-4
pubmed: 32951010
pmcid: 7502082
Okugawa Y, et al. Metastasis-associated long non-coding RNA drives gastric cancer development and promotes peritoneal metastasis. Carcinogenesis. 2014;35(12):2731–9.
doi: 10.1093/carcin/bgu200
pubmed: 25280565
pmcid: 4247518
Li L, et al. The human RNA surveillance factor UPF1 modulates gastric cancer progression by Targeting Long non-coding RNA MALAT1. Cell Physiol Biochem. 2017;42(6):2194–206.
doi: 10.1159/000479994
pubmed: 28942451
Xia H, et al. The lncRNA MALAT1 is a novel biomarker for gastric cancer metastasis. Oncotarget. 2016;7(35):56209–18.
doi: 10.18632/oncotarget.10941
pubmed: 27486823
pmcid: 5302908
Abbastabar M, et al. lncRNA involvement in hepatocellular carcinoma metastasis and prognosis. EXCLI J. 2018;17:900–13.
pubmed: 30564069
pmcid: 6295623
Shi WH, et al. Upregulation of the long noncoding RNA PCAT-1 correlates with advanced clinical stage and poor prognosis in esophageal squamous carcinoma. Tumour Biol. 2015;36(4):2501–7.
doi: 10.1007/s13277-014-2863-3
pubmed: 25731728
Zhang X, et al. Elevated expression of CCAT2 is associated with poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol. 2015;111(7):834–9.
doi: 10.1002/jso.23888
pubmed: 25919911
Wang Y, et al. CRNDE, a long-noncoding RNA, promotes glioma cell growth and invasion through mTOR signaling. Cancer Lett. 2015;367(2):122–8.
doi: 10.1016/j.canlet.2015.03.027
pubmed: 25813405
Di W, et al. The long non-coding RNA HOTAIR promotes thyroid cancer cell growth, invasion and migration through the mir-1-CCND2 axis. Am J Cancer Res. 2017;7(6):1298–309.
pubmed: 28670492
pmcid: 5489779